<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087306</url>
  </required_header>
  <id_info>
    <org_study_id>CMX001-304</org_study_id>
    <nct_id>NCT02087306</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection</brief_title>
  <official_title>A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV)&#xD;
      administered twice weekly for the treatment of adenovirus (AdV) infection detected during&#xD;
      asymptomatic AdV viremia or during symptomatic AdV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 3 open-label, non-randomized, multicenter study of the safety, tolerability,&#xD;
      and efficacy of oral brincidofovir (BCV) when administered twice weekly for the treatment of&#xD;
      disseminated adenovirus (AdV) disease and for the treatment of AdV infection when treatment&#xD;
      was initiated in subjects who were at risk of progression to disseminated disease (i.e.,&#xD;
      during the asymptomatic or localized phases of infection).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With All-Cause Mortality</measure>
    <time_frame>60 days</time_frame>
    <description>The primary efficacy endpoint was the evaluation of the effect of brincidofovir (BCV) on all-cause mortality when used for the treatment of disseminated adenovirus (AdV) disease in all hematopoietic cell transplant (HCT) recipients. The primary endpoint associated with this objective was all-cause mortality through Day 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Reduction in Adenovirus Viremia</measure>
    <time_frame>Assessed 13 weeks (through 7 days post-last BCV dose); during treatment up to 12 weeks reported</time_frame>
    <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Minimum On-treatment Value log10 Copies/mL Change From Baseline</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Adenovirus Infection</condition>
  <arm_group>
    <arm_group_label>Brincidofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brincidofovir</intervention_name>
    <description>BCV administered twice weekly, dose depending on weight.</description>
    <arm_group_label>Brincidofovir</arm_group_label>
    <other_name>BCV</other_name>
    <other_name>CMX001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Subjects were required to meet all of the following criteria, as&#xD;
        applicable, to be eligible to participate in this study.&#xD;
&#xD;
          1. Were male or female, aged 2 months or older.&#xD;
&#xD;
          2. Had either of the following:&#xD;
&#xD;
               -  Disseminated adenovirus (AdV) disease; or&#xD;
&#xD;
               -  An underlying immunocompromised state and were at risk of progression to&#xD;
                  disseminated AdV disease.&#xD;
&#xD;
             [Note: Subjects with symptomatic AdV infection (i.e., localized or disseminated AdV&#xD;
             disease) could have been screening immediately, with brincidofovir (BCV) therapy&#xD;
             initiated after receipt of the screening virology results from the designated central&#xD;
             virology laboratory confirming study eligibility. Subjects with asymptomatic AdV&#xD;
             infection (i.e., had no symptoms of AdV disease) could have been consented and&#xD;
             screened only if they had at least 1 positive or detectable AdV DNA (quantitative [q])&#xD;
             polymerase chain reaction (PCR) test (in any blood fluid or compartment) from the&#xD;
             local virology laboratory, with treatment initiated only after confirmation of AdV&#xD;
             positivity by 2 separate measurements at the designated central virology laboratory.&#xD;
             Where the results from 2 AdV DNA (q)PCR measurements in plasma or non-plasma body&#xD;
             fluid or compartment were needed to show that a subject was at risk of progression to&#xD;
             disseminated AdV disease, the second measurement had to be resulted prior to the&#xD;
             initiation of BCV therapy.]&#xD;
&#xD;
          3. Were able to ingest and absorb oral medication (in the judgement of the investigator&#xD;
             and based on lack of significant gastrointestinal [GI] events/medical history).&#xD;
&#xD;
          4. If male of reproductive potential, were willing to use an acceptable contraceptive&#xD;
             method(s) during sexual intercourse with a female partner of reproductive potential&#xD;
             throughout the duration of this participation in the study and for at least 6 months&#xD;
             after his last dose of BCV.&#xD;
&#xD;
          5. If female of reproductive potential, i.e., not premenarche, postmenopausal, surgically&#xD;
             sterile, or had documented ovarian failure, were willing to use 2 acceptable&#xD;
             contraceptive methods, 1 of which must have been a barrier method, during sexual&#xD;
             intercourse with a nonsterile male partner, throughout the duration of her&#xD;
             participation in the study and for at least 6 months after her last dose of BCV.&#xD;
&#xD;
          6. Were willing and able to understand and provide written informed consent to&#xD;
             participate in the study. [Note: If the subject was under 18 years of age or was&#xD;
             otherwise unable to legally give his or her informed consent to participate in the&#xD;
             study, then written informed consent to participate had to be obtained from the&#xD;
             parent(s) or legal guardian(s) of the subject or other legal personal&#xD;
             representative(s), as applicable. In addition, in the case of minor subjects, the&#xD;
             written assent of the subject to participate in the study was obtained where required&#xD;
             by applicable institutional policy on the consenting of minor study participants.]&#xD;
&#xD;
          7. The subject and his or her caregivers (as applicable) were willing and able to&#xD;
             participate in all required study activities for the entire duration of the study&#xD;
             (i.e., through completion of Week 36).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who met any of the following criteria (as applicable) were not eligible to&#xD;
        participate in this study:&#xD;
&#xD;
          1. If a female of reproductive potential, the subject was pregnant, planning to become&#xD;
             pregnant during the study or within 6 months after their anticipated last BCV dose, or&#xD;
             was nursing a child.&#xD;
&#xD;
          2. Had hypersensitivity (not including renal dysfunction or eye disorder) to cidofovir&#xD;
             (CDV) or to BCV or its formulation excipients.&#xD;
&#xD;
          3. Had received treatment with another investigational drug within 14 days prior to Day 1&#xD;
             unless prior approval was received from the Chimerix medical monitor (or designee).&#xD;
&#xD;
          4. Were participating in another interventional clinical trial unless prior approval was&#xD;
             received from the Chimerix medical monitor (or designee).&#xD;
&#xD;
          5. Had previously received an anti-AdV vaccine or a cell-based anti-AdV therapy.&#xD;
&#xD;
          6. Were receiving intravenous (IV) CDV, leflunomide, vidarabine, systemic ribavirin, or&#xD;
             another investigational anti-AdV drug at Day 1. [Note: Subjects who were receiving&#xD;
             treatment with IV CDV prior to enrollment had to discontinue IV CDV and wait until a&#xD;
             minimum of 48 hours had elapsed from last IV CDV administration before initiating BCV&#xD;
             therapy. All other drugs had to be discontinued prior to Day 1.]&#xD;
&#xD;
          7. Were receiving digoxin or ketoconazole (other than topical formulations) at Day 1 or&#xD;
             were anticipated to need treatment with either drug during the treatment phase of the&#xD;
             study.&#xD;
&#xD;
          8. Were infected with HIV, hepatitis B virus (HBV), and/or hepatitis C virus (HCV), had&#xD;
             evidence of active viral replication within 6 months prior to screening, as&#xD;
             demonstrated by detectable HIV or HCV RNA, or had detectable HBV DNA in blood, plasma&#xD;
             or serum.&#xD;
&#xD;
          9. Had end-stage renal disease, i.e., an estimated glomerular filtration rate &lt;15 mL/min,&#xD;
             unless receiving renal replacement therapy.&#xD;
&#xD;
         10. Had a serum alanine aminotransferase or aspartate aminotransferase concentration &gt;5 x&#xD;
             the upper limit of normal (ULN), or a serum total bilirubin concentration &gt;2 x the ULN&#xD;
             and a serum direct (conjugated) bilirubin concentration &gt;1.5 x the ULN, as reported by&#xD;
             the central safety laboratory, unless, in the judgment of the investigator, the&#xD;
             abnormality(ies) was/were related to the subject's AdV infection/disease.&#xD;
&#xD;
         11. Had ongoing Grade 3 or higher diarrhea, unless, in the judgment of the investigator,&#xD;
             the diarrhea was related to the subject's underlying AdV infection/disease.&#xD;
&#xD;
         12. Had Stage 3 or higher graft versus host disease (GVHD) of the intestine (GI-GVHD or&#xD;
             any other GI disease that would have, in the judgment of the investigator, precluded&#xD;
             the subject from taking or absorbing oral medication (e.g., clinically active Crohn's&#xD;
             disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel&#xD;
             resection, ileus, or any condition expected to require abdominal surgery during the&#xD;
             course of study participation).&#xD;
&#xD;
         13. Had any other condition, including abnormal laboratory values, that would have, in the&#xD;
             judgment of the investigator, put the subject at increased risk by participating in&#xD;
             the study, or would have interfered with the conduct or planned analyses of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta, Aflac Cancer and Blood Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Woman's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montifore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College/ New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchingson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>19024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <results_first_submitted>December 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenovirus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brincidofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A</title>
          <description>Allogeneic hematopoietic cell transplant recipients at risk of progression to disseminated adenovirus (AdV) disease (i.e., subjects with either asymptomatic AdV infection or localized adenovirus disease) and who weighed ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not-to-exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received BCV 100 mg twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
        <group group_id="P2">
          <title>Cohort B</title>
          <description>Allogeneic hematopoietic cell transplant recipients with disseminated adenovirus disease who weigh ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg brincidofovir (BCV; not to exceed 100 mg) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
        <group group_id="P3">
          <title>Cohort C</title>
          <description>Allogeneic hematopoietic cell transplant recipients who weighed &gt;120 kg and all other immunocompromised subjects with disseminated adenovirus (AdV) disease or subjects who were at risk of progression to disseminated AdV disease, as well as non-immunocompromised subjects with disseminated AdV disease.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Allogeneic hematopoietic cell transplant recipients at risk of progression to disseminated adenovirus (AdV) disease (i.e., subjects with either asymptomatic AdV infection or localized adenovirus disease) and who weighed ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not-to-exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received BCV 100 mg twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>Allogeneic hematopoietic cell transplant recipients with disseminated adenovirus disease who weigh ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg brincidofovir (BCV; not to exceed 100 mg) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
        <group group_id="B3">
          <title>Cohort C</title>
          <description>Allogeneic hematopoietic cell transplant recipients who weighed &gt;120 kg and all other immunocompromised subjects with disseminated adenovirus (AdV) disease or subjects who were at risk of progression to disseminated AdV disease, as well as non-immunocompromised subjects with disseminated AdV disease.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="17.4"/>
                    <measurement group_id="B2" value="20" spread="23.1"/>
                    <measurement group_id="B3" value="17" spread="21.9"/>
                    <measurement group_id="B4" value="19" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-Cause Mortality</title>
        <description>The primary efficacy endpoint was the evaluation of the effect of brincidofovir (BCV) on all-cause mortality when used for the treatment of disseminated adenovirus (AdV) disease in all hematopoietic cell transplant (HCT) recipients. The primary endpoint associated with this objective was all-cause mortality through Day 60.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Allogeneic hematopoietic cell transplant recipients at risk of progression to disseminated adenovirus (AdV) disease (i.e., subjects with either asymptomatic AdV infection or localized adenovirus disease) and who weighed ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not-to-exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received BCV 100 mg twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Allogeneic hematopoietic cell transplant recipients with disseminated adenovirus disease who weigh ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg brincidofovir (BCV; not to exceed 100 mg) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
            <description>Allogeneic hematopoietic cell transplant recipients who weighed &gt;120 kg and all other immunocompromised subjects with disseminated adenovirus (AdV) disease or subjects who were at risk of progression to disseminated AdV disease, as well as non-immunocompromised subjects with disseminated AdV disease.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Mortality</title>
          <description>The primary efficacy endpoint was the evaluation of the effect of brincidofovir (BCV) on all-cause mortality when used for the treatment of disseminated adenovirus (AdV) disease in all hematopoietic cell transplant (HCT) recipients. The primary endpoint associated with this objective was all-cause mortality through Day 60.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Reduction in Adenovirus Viremia</title>
        <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
        <time_frame>Assessed 13 weeks (through 7 days post-last BCV dose); during treatment up to 12 weeks reported</time_frame>
        <population>Subjects with AdV viremia at baseline in the Intention-to-Treat Analysis Set. The Intention-to-Treat Analysis Set included all subjects who received at least 1 dose of BCV.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Allogeneic hematopoietic cell transplant recipients at risk of progression to disseminated adenovirus (AdV) disease (i.e., subjects with either asymptomatic AdV infection or localized adenovirus disease) and who weighed ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not-to-exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received BCV 100 mg twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Allogeneic hematopoietic cell transplant recipients with disseminated adenovirus disease who weigh ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg brincidofovir (BCV; not to exceed 100 mg) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
            <description>Allogeneic hematopoietic cell transplant recipients who weighed &gt;120 kg and all other immunocompromised subjects with disseminated adenovirus (AdV) disease or subjects who were at risk of progression to disseminated AdV disease, as well as non-immunocompromised subjects with disseminated AdV disease.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in Adenovirus Viremia</title>
          <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
          <population>Subjects with AdV viremia at baseline in the Intention-to-Treat Analysis Set. The Intention-to-Treat Analysis Set included all subjects who received at least 1 dose of BCV.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undetectable AdV viremia at any time on-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetectable AdV viremia at last on-treatment value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Minimum On-treatment Value log10 Copies/mL Change From Baseline</title>
        <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Subjects who had adenovirus viremia at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Allogeneic hematopoietic cell transplant recipients at risk of progression to disseminated adenovirus (AdV) disease (i.e., subjects with either asymptomatic AdV infection or localized adenovirus disease) and who weighed ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not-to-exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received BCV 100 mg twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Allogeneic hematopoietic cell transplant recipients with disseminated adenovirus disease who weigh ≤120 kg.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg brincidofovir (BCV; not to exceed 100 mg) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
            <description>Allogeneic hematopoietic cell transplant recipients who weighed &gt;120 kg and all other immunocompromised subjects with disseminated adenovirus (AdV) disease or subjects who were at risk of progression to disseminated AdV disease, as well as non-immunocompromised subjects with disseminated AdV disease.&#xD;
Subjects who weighed &lt;50 kg received 2 mg/kg (not to exceed 100 mg) brincidofovir (BCV) twice weekly, administered orally as the appropriate volume of 10-mg/mL liquid suspension.&#xD;
Subjects who weighed ≥50 kg received 100 mg BCV twice weekly, administered orally as one 100-mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Minimum On-treatment Value log10 Copies/mL Change From Baseline</title>
          <description>A secondary endpoint was the evaluation of virologic response (plasma adenovirus [AdV] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10^10 copies/mL. A &quot;positive or detectable&quot; result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).</description>
          <population>Subjects who had adenovirus viremia at baseline.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum on-treatment value log10 copies/mL change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" spread="1.559"/>
                    <measurement group_id="O2" value="-3.27" spread="2.163"/>
                    <measurement group_id="O3" value="-3.11" spread="2.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last on-treatment value log10 copies/mL change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.898"/>
                    <measurement group_id="O2" value="-2.61" spread="2.338"/>
                    <measurement group_id="O3" value="-2.87" spread="2.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that started on or after the first dose of BCV up to 7 days after the last dose of BCV (through 13 weeks) are reported.</time_frame>
      <desc>As specified in the Statistical Analysis Plan, adverse events were reported by age group (i.e., pediatric and adult) rather than by cohort to provide a more useful safety assessment. Differentiating pediatric from adult safety in this broad population was more useful than differentiating safety by cohort in this uncontrolled setting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pediatric</title>
          <description>Subjects aged 2 months to &lt;18 years.</description>
        </group>
        <group group_id="E2">
          <title>Adult</title>
          <description>Subjects aged ≥18 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Metachromatic leukodystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Faecal volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ileal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Device-related infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Escherichia baceraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Viral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Adenoviral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bacillus bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Clostridium bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cronobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Enteroabacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fusarium infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltranferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Chimerix, Inc.</organization>
      <phone>919-806-1074 ext 101</phone>
      <email>dmoore@chimerix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

